Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640233 | 1.00 | CYP2A6 (0.64) | CYP2A6KEAP1NFE2L2TDP1CA2 | |
| SCHEMBL1121640 | 0.85 | CYP2A6 (0.56) | CYP2A6KEAP1NFE2L2TDP1CA2 | |
| SCHEMBL5397554 | 0.78 | CYP2A6 (0.64) | CYP2A6CA2ERN1PTPN1MAPT | |
| SCHEMBL19735067 | 0.78 | CYP2A6 (0.64) | CYP2A6TDP1ERN1MAPT | |
| SCHEMBL2022637 | 0.78 | CYP2A6 (1.00) | CYP2A6CA2ERN1PTPN1MAPT | |
| SCHEMBL7332731 | 0.78 | CYP2A6 (0.64) | CYP2A6CA2ERN1SMN1; SMN2MAPT | |
| SCHEMBL3682441 | 0.76 | CYP2A6 (0.62) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL29017448 | 0.74 | CYP2A6 (0.64) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL16619089 | 0.74 | CYP2A6 (0.58) | CYP2A6ERN1SMN1; SMN2MAPTLMNA | |
| SCHEMBL20954428 | 0.74 | CYP2A6 (0.58) | CYP2A6CA2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |